1. 3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma. (September 2015) Authors: Van Herpen, C.; Postow, M.A.; Carlino, M.S.; Kalkavan, H.; Weise, A.; Amaria, R.N.; Vos, F. De; Carvajal, R.D.; Matano, A.; Bhansali, S.; Lam, L.; Yerramilli-Rao, P.; Sosman, J.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 503 Pneumonitis with anti-PD-1/PD-L1 therapy. (September 2015) Authors: Naidoo, J.; Cunningham, J.; Woo, K.M.; Hellmann, M.D.; Postow, M.A.; Drilon, A.E.; Chaft, J.E.; Lesokhin, A.M.; Segal, N.H.; Callahan, M.K.; Rudin, C.M.; Iyriboz, T.; Wolchok, J.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. (1st January 2018) Authors: Wolner, Z.J.; Marghoob, A.A.; Pulitzer, M.P.; Postow, M.A.; Marchetti, M.A. Journal: British journal of dermatology Issue: Volume 178:Number 1(2018) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. (21st September 2017) Authors: Wolner, Z.J.; Marghoob, A.A.; Pulitzer, M.P.; Postow, M.A.; Marchetti, M.A. Journal: British journal of dermatology Issue: Volume 178:Number 1(2018) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. (June 2016) Authors: Belum, V.R.; Benhuri, B.; Postow, M.A.; Hellmann, M.D.; Lesokhin, A.M.; Segal, N.H.; Motzer, R.J.; Wu, S.; Busam, K.J.; Wolchok, J.D.; Lacouture, M.E. Journal: European journal of cancer Issue: Volume 60(2016) Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. (1st June 2017) Authors: Zarbo, A.; Belum, V.R.; Sibaud, V.; Oudard, S.; Postow, M.A.; Hsieh, J.J.; Motzer, R.J.; Busam, K.J.; Lacouture, M.E. Journal: British journal of dermatology Issue: Volume 176:Number 6(2017) Page Start: 1649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. (24th April 2017) Authors: Zarbo, A.; Belum, V.R.; Sibaud, V.; Oudard, S.; Postow, M.A.; Hsieh, J.J.; Motzer, R.J.; Busam, K.J.; Lacouture, M.E. Journal: British journal of dermatology Issue: Volume 176:Number 6(2017) Page Start: 1649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗